What Are the Infection-Related Economic Outcomes of TKI Use in CML?
Researchers reviewed 2 administrative databases of claims for adults with newly diagnosed chronic myeloid leukemia (CML) who received dastatinib or nilotinib as first-line therapy (n = 1156 vs 677, respectively) or as second-line therapy (n = 322 vs 207, respectively). Dasatinib was associated with greater healthcare resource utilization (HRU) and greater costs than nilotinib in the first-line and second-line cohorts, with infection as the primary driver. In the first-line cohort, annual infection-related costs per person were 34% higher ($6048) with dasatinib than with nilotinib. In the second-line cohort, annual infection-related costs were 99% higher ($28,192) with dastatinib than with nilotinib. The study was sponsored by Novartis.
Read more here.
Reference
Seiter K, Latremouille-Viau D, Guerin A, et al. Burden of infections among chronic myeloid leukemia patients receiving dasatinib or nilotinib: a real-world retrospective healthcare claims study in the United States. Adv Ther. 2018 Aug 28. doi: 10.1007/s12325-018-0772-3.
